AstraZeneca to pay for access to saRNA platform

23 September 2021

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.

VaxEquity was founded only last year by Imperial College London and life sciences investor Morningside Ventures, based on the innovative saRNA technology developed by Robin Shattock, head of Immunology of Infection within the Department of Infectious Diseases, and his colleagues at the UK university.

"We aim to underpin the next generation of RNA-delivered medicines enabling not only vaccines but also broad range of therapeutics applications"saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK